These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 24276954)
1. Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network. Hori K; Kobayashi N; Atsumi H; Nagayama A; Kondoh M; Noge I; Kimura M; Utsugi H; Iwasaki T; Nakamura M; Kimura T Support Care Cancer; 2014 Apr; 22(4):969-77. PubMed ID: 24276954 [TBL] [Abstract][Full Text] [Related]
2. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data. Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084 [TBL] [Abstract][Full Text] [Related]
3. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M; Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of Adherence to Antiemetic Treatment Guidelines in Patients With Chemotherapy-Induced Nausea and Vomiting in Teaching Hospitals in Tehran. Nikbakht Z; Rajabi M; Shahrasbi A; Roohi E; Hashemian F J Cancer Educ; 2021 Oct; 36(5):1022-1029. PubMed ID: 31955393 [TBL] [Abstract][Full Text] [Related]
5. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan. Iihara H; Shimokawa M; Hayashi T; Kawazoe H; Saeki T; Aiba K; Tamura K Oncologist; 2020 Feb; 25(2):e373-e380. PubMed ID: 32043774 [TBL] [Abstract][Full Text] [Related]
6. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study. Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the compliance with antiemetic guidelines for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancy. Uchida M; Nakamura T; Shima T; Mori Y; Yoshimoto G; Kato K; Shimokawa M; Hosohata K; Miyamoto T; Akashi K Pharmazie; 2019 Apr; 74(4):250-254. PubMed ID: 30940311 [TBL] [Abstract][Full Text] [Related]
8. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis. Natale JJ Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912 [TBL] [Abstract][Full Text] [Related]
9. The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group. Araz M; Karaagac M; Korkmaz L; Beypinar I; Uysal M Curr Probl Cancer; 2019 Aug; 43(4):344-353. PubMed ID: 30497851 [TBL] [Abstract][Full Text] [Related]
10. Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey. Vidall C; Fernández-Ortega P; Cortinovis D; Jahn P; Amlani B; Scotté F Support Care Cancer; 2015 Nov; 23(11):3297-305. PubMed ID: 25953380 [TBL] [Abstract][Full Text] [Related]
11. Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey. Aapro M; Ruffo P; Panteri R; Costa S; Piovesana V Cancer Rep (Hoboken); 2018 Dec; 1(4):e1127. PubMed ID: 32729252 [TBL] [Abstract][Full Text] [Related]
12. Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice. Affronti ML; Schneider SM; Herndon JE; Schlundt S; Friedman HS Support Care Cancer; 2014 Jul; 22(7):1897-905. PubMed ID: 24570103 [TBL] [Abstract][Full Text] [Related]
13. Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. Takeuchi H; Saeki T; Aiba K; Tamura K; Aogi K; Eguchi K; Okita K; Kagami Y; Tanaka R; Nakagawa K; Fujii H; Boku N; Wada M; Akechi T; Udagawa Y; Okawa Y; Onozawa Y; Sasaki H; Shima Y; Shimoyama N; Takeda M; Nishidate T; Yamamoto A; Ikeda T; Hirata K Int J Clin Oncol; 2016 Feb; 21(1):1-12. PubMed ID: 26081252 [TBL] [Abstract][Full Text] [Related]
14. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Aogi K; Takeuchi H; Saeki T; Aiba K; Tamura K; Iino K; Imamura CK; Okita K; Kagami Y; Tanaka R; Nakagawa K; Fujii H; Boku N; Wada M; Akechi T; Iihara H; Ohtani S; Okuyama A; Ozawa K; Kim YI; Sasaki H; Shima Y; Takeda M; Nagasaki E; Nishidate T; Higashi T; Hirata K Int J Clin Oncol; 2021 Jan; 26(1):1-17. PubMed ID: 33161452 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Hilarius DL; Kloeg PH; van der Wall E; van den Heuvel JJ; Gundy CM; Aaronson NK Support Care Cancer; 2012 Jan; 20(1):107-17. PubMed ID: 21258948 [TBL] [Abstract][Full Text] [Related]
16. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan. Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M; Int J Clin Oncol; 2017 Apr; 22(2):405-412. PubMed ID: 27909835 [TBL] [Abstract][Full Text] [Related]
17. Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk. Shimokawa M; Hayashi T; Nishimura J; Satoh T; Fukunaga M; Matsui R; Tsuji Y; Mizuki F; Kogawa T BMC Cancer; 2021 Oct; 21(1):1111. PubMed ID: 34656107 [TBL] [Abstract][Full Text] [Related]
18. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. dos Santos LV; Souza FH; Brunetto AT; Sasse AD; da Silveira Nogueira Lima JP J Natl Cancer Inst; 2012 Sep; 104(17):1280-92. PubMed ID: 22911671 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan. Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]